Which feature best distinguishes ciprofloxacin from levofloxacin in terms of clinical pharmacology and spectrum?

Explanation

## Distinguishing Ciprofloxacin from Levofloxacin ### Structural and Pharmacological Basis Levofloxacin is the L-isomer (active enantiomer) of ofloxacin, whereas ciprofloxacin is a racemic mixture. This structural difference confers distinct pharmacological properties. ### Key Differences in Spectrum | Feature | Ciprofloxacin | Levofloxacin | |---------|---------------|---------------| | **Gram-positive coverage** | Moderate (less reliable for pneumococci) | Superior (excellent for *S. pneumoniae*, MSSA) | | **Gram-negative coverage** | Excellent (best-in-class) | Good but inferior to cipro | | **Anaerobic coverage** | Minimal | Minimal | | **Atypical bacteria** | Good | Excellent | | **Intracellular penetration** | Moderate | Superior | **Key Point:** Levofloxacin is the preferred fluoroquinolone for respiratory infections (*S. pneumoniae*, *Legionella*, *Mycoplasma*) and urinary tract infections due to superior gram-positive and atypical coverage. Ciprofloxacin remains the drug of choice for gram-negative organisms (especially *Pseudomonas aeruginosa*) and GI infections. **High-Yield:** Levofloxacin = respiratory and UTI fluoroquinolone; Ciprofloxacin = gram-negative and *Pseudomonas* fluoroquinolone. **Clinical Pearl:** In a patient with community-acquired pneumonia and concern for pneumococcal coverage, levofloxacin is preferred over ciprofloxacin because of superior *S. pneumoniae* MICs and lung penetration. ### Why Levofloxacin Excels in Respiratory Infections Being the pure L-isomer, levofloxacin achieves higher intracellular and tissue concentrations, making it ideal for atypical pathogens and intracellular organisms. Its enhanced gram-positive activity (particularly against penicillin-susceptible and intermediate *S. pneumoniae*) makes it a reliable monotherapy for CAP. [cite:KD Tripathi 8e Ch 47]